JAK2 and essential thrombocythemia: Therapeutically, all PV patients receive low-dose aspirin and are phlebotomized with an aim to maintain the hematocrit < 45% as two randomized clinical trials have shown that these interventions may lower cardiovascular risk, whereas ET patients usually receive aspirin if they have previously experienced thrombosis or are JAK2 positive.